PHARSCIN PHARMA

PHARSCIN PHARMA (Stock abbreviation: PHARSCIN PHARMA, Stock code: 002907) is a key national high-tech enterprise integrating pharmaceutical research, production, and sales, as well as a Shenzhen Stock Exchange A-share listed company. Over the years, the company has successively been awarded honors such as National Enterprise Technology Center, National Technological Innovation Demonstration Enterprise, Advanced Private Enterprise in Employment and Social Security in China, Quality Award of Healthy China, China Patent Award, Top 100 OTC Pharmaceutical Enterprises in China for 2019, Benchmark Pharmaceutical Enterprise of the 70th Anniversary of the Founding of the People's Republic of China, National Contract-abiding and Credit-valuing Enterprise, National Intellectual Property Demonstration Enterprise, Top 100 Chinese Medicine Enterprises in China for 2019, Most Growth-oriented Pharmaceutical Industrial Enterprise in China for 2020, Advanced Grassroots Party Organization in Chongqing, Outstanding Application Award of China’s Industrial Internet for 2021, among others. It has also established a postdoctoral research workstation and the Chongqing HaiZhi Workstation. PHARSCIN PHARMA oversees subsidiaries including Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Chain Co., Ltd., and Pharscin US Inc. (PHARSCIN PHARMA USA). Guided by the concept of "Technology-led, Innovation-driven, Inheriting Essence, Upholding Integrity, and Innovating," PHARSCIN PHARMA creates high-quality products that are specialized, precise, distinctive, and innovative. Currently, the company owns 74 drug approval numbers, including traditional Chinese medicine, chemical raw materials, and preparations, of which 53 are included in the National Medical Insurance Catalogue. The company has formulated 49 national drug standards, holds 72 patents, and has undertaken 120 scientific research projects at the national, provincial, and municipal levels. In terms of innovative drug R&D, PHARSCIN PHARMA is advancing its innovative drug development strategy, focusing on the development of First-In-Class and Best-In-Class drugs, promoting differentiated R&D pipelines, and is committed to building an innovative drug R&D team with international vision. At present, the company has four self-developed Class 1.1 innovative anti-tumor drugs under research, with potential indications covering tumor immunotherapy, as well as lung cancer, breast cancer, colorectal cancer, pancreatic cancer, and other solid tumors. It has built three major innovative drug technology platforms: a bioactivity screening platform for molecularly targeted drugs based on functional genomics, a druggability evaluation platform for drug metabolism and pharmacokinetics testing, and a small molecule drug structure design and synthesis platform for specific targets. These platforms provide capabilities for innovative drug discovery through preclinical development, achieving breakthroughs from 0 to 1 in innovative drug development.